Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions.

Kussmann M, Ferth A, Obermüller M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Poeppl W, Reznicek G.

Sci Rep. 2019 Apr 24;9(1):6512. doi: 10.1038/s41598-019-42854-y.

2.

A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health.

Vychytil A, Herzog R, Probst P, Ribitsch W, Lhotta K, Machold-Fabrizii V, Wiesholzer M, Kaufmann M, Salmhofer H, Windpessl M, Rosenkranz AR, Oberbauer R, König F, Kratochwill K, Aufricht C.

Kidney Int. 2018 Dec;94(6):1227-1237. doi: 10.1016/j.kint.2018.08.031. Epub 2018 Oct 22.

3.

Compatibility of linezolid with commercial peritoneal dialysis solutions.

Poeppl W, Rainer-Harbach E, Kussmann M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Reznicek G.

Am J Health Syst Pharm. 2018 Oct 1;75(19):1467-1477. doi: 10.2146/ajhp170318.

PMID:
30257843
4.

Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa.

Kussmann M, Hauer S, Pichler P, Reznicek G, Burgmann H, Poeppl W, Zeitlinger M, Wiesholzer M.

Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1091-1098. doi: 10.1007/s10096-018-3221-y. Epub 2018 Mar 15.

5.

Compatibility of fosfomycin with different commercial peritoneal dialysis solutions.

Kussmann M, Baumann A, Hauer S, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Poeppl W, Reznicek G.

Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2237-2242. doi: 10.1007/s10096-017-3051-3. Epub 2017 Jul 6.

6.

Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.

Kussmann M, Schuster L, Wrenger S, Pichler P, Reznicek G, Burgmann H, Poeppl W, Zeitlinger M, Wiesholzer M.

Perit Dial Int. 2016 11-12;36(6):662-668. Epub 2016 Sep 28.

7.

Compatibility of Meropenem with Different Commercial Peritoneal Dialysis Solutions.

Wiesholzer M, Winter A, Kussmann M, Zeitlinger M, Pichler P, Burgmann H, Reznicek G, Poeppl W.

Perit Dial Int. 2017 1-2;37(1):51-55. doi: 10.3747/pdi.2016.00018. Epub 2016 Sep 7.

PMID:
27605684
8.

An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis.

Wiesholzer M, Pichler P, Reznicek G, Wimmer M, Kussmann M, Balcke P, Burgmann H, Zeitlinger M, Poeppl W.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2790-7. doi: 10.1128/AAC.02664-15. Print 2016 May.

9.

Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study.

Lammerich A, Balcke P, Bias P, Mangold S, Wiesholzer M.

Clin Ther. 2016 Feb;38(2):276-287.e4. doi: 10.1016/j.clinthera.2015.11.018. Epub 2015 Dec 19.

PMID:
26708119
10.

The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis.

Kussmann M, Schuster L, Zeitlinger M, Pichler P, Reznicek G, Wiesholzer M, Burgmann H, Poeppl W.

Eur J Clin Microbiol Infect Dis. 2015 Nov;34(11):2257-63. doi: 10.1007/s10096-015-2477-8. Epub 2015 Sep 4.

PMID:
26337433
11.

Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis.

Kerschbaum J, Vychytil A, Lhotta K, Prischl FC, Wiesholzer M, Machhold-Fabrizii V, Kopriva-Altfahrt G, Schwarz C, Balcke P, Oberbauer R, Kramar R, König P, Rudnicki M.

PLoS One. 2013 Jul 2;8(7):e67836. doi: 10.1371/journal.pone.0067836. Print 2013.

12.

[Assisted peritoneal dialysis: home-based renal replacement therapy for the elderly patient].

Wiesholzer M.

Wien Med Wochenschr. 2013 Jun;163(11-12):280-7. Review. German.

PMID:
23797681
13.

The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin.

Watschinger B, Salmhofer H, Horn S, Neyer U, Wiesinger T, Wiesholzer M, Erb H, Jaeger C, Hemetsberger M, Rosenkranz AR.

Wien Klin Wochenschr. 2013 Feb;125(3-4):71-82. doi: 10.1007/s00508-012-0311-1. Epub 2013 Jan 9.

PMID:
23299452
14.

Exit-site care in Austrian peritoneal dialysis centers -- a nationwide survey.

Kopriva-Altfahrt G, König P, Mündle M, Prischl F, Roob JM, Wiesholzer M, Vychytil A; Austrian Study Group for Prevention of Peritoneal Catheter-Associated Infections, Arneitz K, Karner A, Artes R, Wolf E, Auinger M, Pawlak A, Fraberger J, Hofbauer S, Galvan G, Salmhofer H, Pichler B, Wazel M, Gruber M, Thonhofer A, Hager A, Malajner S, Heiss S, Braunsteiner T, Zweiffler M, König P, Rudnicki M, Kogler R, Kohlhauser D, Wiesinger T, Kopriva-Altfahrt G, Moser E, Kotanko P, Loibner H, Nitz H, Miska HJ, Wenzel R, Wölfer M, Mündle M, Breuss H, Hölzl B, Prischi F, Schmekal B, Riener EM, Roob JM, Wonisch W, Vikydal R, Vychytil A, Frank B, Wieser C, Wiesholzer M, Pokorny K.

Perit Dial Int. 2009 May-Jun;29(3):330-9.

PMID:
19458307
15.

[Peritoneal dialysis and cardiopulmonary comorbidity].

Wiesholzer M.

Wien Klin Wochenschr. 2005;117 Suppl 6:46-53. Review. German.

PMID:
16437333
16.

Hormonal profile and fertility in patients with Anderson-Fabry disease.

Hauser AC, Gessl A, Harm F, Wiesholzer M, Kleinert J, Wallner M, Voigtländer T, Bieglmayer C, Sunder-Plassmann G.

Int J Clin Pract. 2005 Sep;59(9):1025-8.

PMID:
16115176
17.

Results of a nationwide screening for Anderson-Fabry disease among dialysis patients.

Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Födinger M, Sunder-Plassmann G.

J Am Soc Nephrol. 2004 May;15(5):1323-9. Erratum in: J Am Soc Nephrol. 2004 Aug;15(8):1a. J Am Soc Nephrol. 2004 Sep;15(9):A4.

18.

Initial body mass indexes have contrary effects on change in body weight and mortality of patients on maintenance hemodialysis treatment.

Wiesholzer M, Harm F, Schuster K, Putz D, Neuhauser C, Fiedler F, Balcke P.

J Ren Nutr. 2003 Jul;13(3):174-85.

PMID:
12874741
19.

Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients.

Kronenberg F, Lingenhel A, Neyer U, Lhotta K, König P, Auinger M, Wiesholzer M, Andersson H, Dieplinger H.

Kidney Int Suppl. 2003 May;(84):S113-6.

PMID:
12694323
20.

Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation.

Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P.

Am J Nephrol. 2001 Jan-Feb;21(1):35-9.

PMID:
11275630
21.

Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin.

Wiesholzer M, Kitzwögerer M, Harm F, Barbieri G, Hauser AC, Pribasnig A, Bankl H, Balcke P.

Am J Kidney Dis. 1999 Apr;33(4):702-8.

PMID:
10196012
22.

Inappropriately high plasma leptin levels in obese haemodialysis patients can be reduced by high flux haemodialysis and haemodiafiltration.

Wiesholzer M, Harm F, Hauser AC, Pribasnig A, Balcke P.

Clin Sci (Lond). 1998 Apr;94(4):431-5.

PMID:
9640349
23.

Major determinants of hyperhomocysteinemia in peritoneal dialysis patients.

Vychytil A, Födinger M, Wölfl G, Enzenberger B, Auinger M, Prischl F, Buxbaum M, Wiesholzer M, Mannhalter C, Hörl WH, Sunder-Plassmann G.

Kidney Int. 1998 Jun;53(6):1775-82.

24.

BLT-esterase in infectious mononucleosis.

Wagner L, Wiesholzer M, Worman CP, Lang G, Base W.

Clin Exp Immunol. 1995 May;100(2):223-6.

25.

Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.

Sexl V, Wagner L, Wiesholzer M, Presterl E, Base W.

Clin Investig. 1994 Mar;72(4):317-20.

PMID:
8043983
26.

In vivo and in vitro primed lymphocytes. Correlation of cytochemically detected BLT-specific lymphoid serine protease with cytotoxic activity.

Wagner L, Sunder-Plassmann G, Base W, Wiesholzer M, Sexl V, Lang G, Worman CP.

J Immunol Methods. 1993 Apr 2;160(2):173-80.

PMID:
7681458
27.

Incidence and phenotype restriction of lymphoid BLT-serine protease granules in spontaneously diabetes prone BB rats compared with a normal rat strain.

Wagner L, Base W, Wiesholzer M, Sexl V, Fürnsinn C, Lang G, Froschauer J, Waldhäusl W.

J Autoimmun. 1992 Oct;5(5):581-90.

PMID:
1418295
28.

Supplemental Content

Loading ...
Support Center